Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

Phase 2

Recruiting

Conditions: Non-transfusion Dependent Beta-thalassemia (NTDT)

Interventions: Drug: REGN7999
Drug: Placebo

First Posted Date: 2024-05-20

Last Posted Date: 2025-04-15

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 95

Registration Number: NCT06421636

Locations: 🇮🇳
Nirmal Hospital Pvt. Ltd - Surat, Surat, Gujarat, India
🇮🇳
Amrita Institute of Medical Sciences and Research Centre (AIMS), Kochi, Kerala, India
🇹🇭
Srinagarind Hospital, Maung, Khon Kaen, Thailand

and more 16 locations

A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies

Phase 1

Recruiting

Conditions: Clear-Cell Renal-Cell Carcinoma (ccRCC)
Advanced Solid Tumors
Melanoma

Interventions: Drug: REGN10597

First Posted Date: 2024-05-14

Last Posted Date: 2025-04-01

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 150

Registration Number: NCT06413680

Locations: 🇺🇸
Yale School of Medicine, North Haven, Connecticut, United States
🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 8 locations

An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting

Withdrawn

Conditions: Neovascular Age-related Macular Degeneration (nAMD)
Wet Age-related Macular Degeneration (AMD)
Diabetic Macular Edema (DME)
Visual Impairment

Interventions: Drug: aflibercept 8 mg

First Posted Date: 2024-05-03

Last Posted Date: 2024-11-25

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 800

Registration Number: NCT06398080

Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

Phase 2

Withdrawn

Conditions: Cutaneous Squamous Cell Carcinoma

Interventions: Drug: cemiplimab
Drug: fianlimab

First Posted Date: 2024-04-25

Last Posted Date: 2024-07-26

Lead Sponsor: Regeneron Pharmaceuticals

Registration Number: NCT06384820

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

Phase 1

Recruiting

Conditions: Hemophilia B

Interventions: Drug: REGV131
Drug: LNP1265

First Posted Date: 2024-04-23

Last Posted Date: 2025-05-22

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 130

Registration Number: NCT06379789

Locations: 🇺🇸
Yale HTC, New Haven, Connecticut, United States
🇺🇸
Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
🇬🇧
Addenbrooke's Hospital, Cambridge University Hospitals NHS FT, Cambridge, United Kingdom

and more 6 locations

Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

Phase 1

Recruiting

Conditions: Food Allergy

Interventions: Drug: linvoseltamab
Drug: dupilumab

First Posted Date: 2024-04-17

Last Posted Date: 2025-05-14

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 6

Registration Number: NCT06369467

Locations: 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸
Emory University- Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 4 locations

First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

Phase 1

Recruiting

Conditions: Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Amyotrophic Lateral Sclerosis (ALS)

Interventions: Drug: ALN-SOD
Other: Diluent
Drug: Placebo (PB)

First Posted Date: 2024-04-08

Last Posted Date: 2025-02-26

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT06351592

Locations: 🇨🇦
University Hospital - London Health Sciences Centre, London, Ontario, Canada
🇨🇦
University of Alberta Hospital, Edmonton, Edmonton, Alberta, Canada
🇨🇦
Sunnybrook Research Institute, Toronto, Ontario, Canada

and more 7 locations

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

Phase 2

Recruiting

Conditions: Venous Thromboembolism

Interventions: Drug: REGN9933
Drug: REGN7508
Drug: Placebo

First Posted Date: 2024-03-07

Last Posted Date: 2025-05-11

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 195

Registration Number: NCT06299111

Locations: 🇮🇱
Lanadio Medical Center, Netanya, Israel
🇨🇦
London Health Sciences Centre, London, Ontario, Canada
🇧🇬
Sveta Sofia Hospital, Sofia, Bulgaria

and more 9 locations

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss

Phase 2

Recruiting

Conditions: Obesity

Interventions: Drug: Trevogrumab-Part B and Part C
Drug: Matching Placebo-Part A
Drug: Trevogrumab-Part A
Drug: Semaglutide
Drug: Garetosmab
Drug: Matching Placebo-Garetosmab
Drug: Matching Placebo-Trevogrumab

First Posted Date: 2024-03-07

Last Posted Date: 2025-05-11

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 999

Registration Number: NCT06299098

Locations: 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸
Cullman Clinical Trials, Cullman, Alabama, United States
🇺🇸
Foothills Research Center Cct Research, Phoenix, Arizona, United States

and more 58 locations

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Phase 1

Recruiting

Conditions: Relapsed/Refractory Systemic Light Chain Amyloidosis

Interventions: Drug: Linvoseltamab

First Posted Date: 2024-03-05

Last Posted Date: 2025-04-16

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 220

Registration Number: NCT06292780

Locations: 🇺🇸
Colorado Blood Cancer Institute/SCRI, Denver, Colorado, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

and more 13 locations

Home Terms & Conditions Privacy Policy